Celera Genomics (CRA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celera Genomics (CRA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Raymond Clutts who started this subject	9/30/2003 1:55:59 PM
From: tom pope	Read Replies (1) of 746

Briefing 13:21 ET CRA Celera Genomics upped to Mkt Perform at Piper Jaffray; tgt $13 (12.00 +0.72) USB Piper Jaffray upgrades stock to Mkt Perform from Underperform after co announced the discovery of genetic biomarkers linked to myocardial infarction. While firm is not changing its forecasts based on this news, Piper does look for increased positive news flow to serve as valuation drivers for CRA as investors begin to assign value to co's early discovery efforts. Price tgt goes to $13 from $10.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next